ORTIN LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20 INR | +1.52% |
|
+4.17% | -13.42% |
| Feb. 17 | Ortin Laboratories Limited Announces Board Appointments | CI |
| Feb. 13 | Ortin Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Sales 2022 | 82.31M 988K | Sales 2023 | 60.2M 723K | Capitalization | 141M 1.7M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -36.02K | Net income 2023 | - 0 | EV / Sales 2022 | 2.92 x |
| Net Debt 2022 | 56.52M 679K | Net Debt 2023 | 62.27M 748K | EV / Sales 2023 | 3.38 x |
| P/E ratio 2022 |
-46.1
x | P/E ratio 2023 |
-145
x | Employees | 24 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.93% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.52% | ||
| 1 week | +4.17% | ||
| Current month | +13.96% | ||
| 1 month | +16.28% | ||
| 3 months | -9.09% | ||
| 6 months | +11.11% | ||
| Current year | -13.42% |
1 week
19.10
20.60
1 month
16.2022.00
Current year
16.2023.60
1 year
16.2030.35
3 years
16.2052.25
5 years
14.1770.73
10 years
14.1787.92
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | 58 | 08-01-28 | |
Divya Purswani
CMP | Compliance Officer | - | Feb. 08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 58 | 08-01-28 | |
| Chief Executive Officer | - | - | |
| Director/Board Member | 61 | 08-01-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 20 | +1.52% | 5 331 |
| 24-04-25 | 19.7 | -1.25% | 6,370 |
| 24-04-24 | 19.95 | +2.05% | 31,442 |
| 24-04-23 | 19.55 | +1.03% | 6,350 |
| 24-04-22 | 19.35 | +0.78% | 23,964 |
Delayed Quote NSE India S.E., April 26, 2024 at 06:02 am EDT
More quotes
Ortin Laboratories Limited is engaged in manufacturing and trading of pharmaceuticals, drugs, and intermediates. It manufactures a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. The Company's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. It is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.
Sector
Pharmaceuticals
Calendar
2024-05-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +25.28% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.36% | 233B | |
| +5.41% | 201B | |
| -10.27% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- ORTINLAB Stock
- ORTINLAB Stock
